Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -37,340 | -29,204 | -19,937 | -11,097 | -41,301 |
| Accounts payable and accrued liabilities | 2,301 | 983 | 377 | -284 | 1,213 |
| Other Working Capital | 3,345 | 659 | -1,051 | -1,655 | 5,641 |
| Other Operating Activity | 284 | 977 | 918 | 909 | 10,638 |
| Operating Cash Flow | $-31,410 | $-26,585 | $-19,693 | $-12,127 | $-23,809 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | -5,500 | -5,500 | -2,500 | N/A | -4,500 |
| Other Investing Activity | -5,500 | -5,500 | -2,500 | 0 | -4,500 |
| Investing Cash Flow | $-5,500 | $-5,500 | $-2,500 | $N/A | $-4,500 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 22,346 | 18,929 | 18,875 | 18,904 | 24,079 |
| Other Financing Activity | -31 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $22,315 | $18,929 | $18,875 | $18,904 | $24,079 |
| Beginning Cash Position | 17,225 | 17,225 | 17,225 | 17,225 | 21,455 |
| End Cash Position | 2,630 | 4,069 | 13,907 | 24,002 | 17,225 |
| Net Cash Flow | $-14,595 | $-13,156 | $-3,318 | $6,777 | $-4,230 |
| Free Cash Flow | |||||
| Operating Cash Flow | -31,410 | -26,585 | -19,693 | -12,127 | -23,809 |
| Free Cash Flow | -31,410 | -26,585 | -19,693 | -12,127 | -23,809 |